PMI U.S., the American arm of Philip Morris International, announced the expansion of its ZYN nicotine pouch portfolio to include new strengths and a new product line, ZYN ULTRA, offering legal-age adults more smoke-free choices. The flagship ZYN dry pouch lineup now includes 1.5 mg and 8 mg strengths in addition to the existing 3 mg and 6 mg, while ZYN ULTRA, a moist pouch with higher moisture content, received FDA marketing authorization for 11 products in August 2026, including ten 9 mg and one 11 mg strengths. These additions build on ZYN's status as the first nicotine pouch authorized by the FDA in January 2025 and the first to receive modified risk tobacco product orders in June 2026, allowing PMI to communicate reduced health risks compared to cigarettes. In Q4, PMI U.S. will transition its 3 mg and 6 mg dry pouches to 20 pouches per can, a preferred package size. CEO Stacey Kennedy emphasized the company's commitment to providing alternatives for the 45 million legal-age American nicotine users, with ZYN manufactured in the U.S., including a new facility in Aurora, Colorado.
Philip Morris International IncPMI U.S. expands ZYN portfolio with new strengths and FDA-authorized ZYN ULTRA product line, broadening its smoke-free product offering.
